PGY2 Clinical Pharmacogenomics Resident St Jude Children's Research Hospital Memphis, Tennessee, United States
Poster Abstract:
Background: Patients with cancer are frequently prescribed medications with pharmacogenomic actionability. Over 95% of these patients have at least one reported high-risk pharmacogenomic test result. One notable barrier to pharmacogenomic implementation is the uncertainty about the true clinical burden of variant alleles, particularly when accounting for those genes having the greatest clinical utility for patient outcomes. There are a limited number of publications that describe the frequencies of pharmacogenomically actionable medication use and high-risk pharmacogenomic phenotypes in the pediatric oncology population.
Objective(s): This study aims to describe the overall use of pharmacogenomically actionable medications and frequencies of pharmacogenomic phenotypes in patients with cancer at St. Jude Children’s Research Hospital (St. Jude).
Methods: This is a descriptive, cross-sectional study evaluating pharmacogenomic test results and medication use at St. Jude between May 2011 and December 2021. Data from 12 pharmacogenes (CACNA1S, CYP2C19, CYP2C9, CYP2D6. CYP3A5, CYP2B6, DPYD, G6PD, MT-RNR1, RYR1, TPMT, NUDT15) and 33 pharmacogenomically actionable medications were assessed. Patients who received a pharmacogenomically actionable medication and had a diagnosis of an oncologic disorder were included in the analysis. Descriptive statistics were used to report frequencies of high-risk phenotypes by gene and use of pharmacogenomically actionable medications.
Results: Results pending.
Discussion/conclusion: Results pending.
References (must also be included in final poster): Hicks JK, El Rouby N, Ong HH, et al. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021;110(1):179-188. doi:10.1002/cpt.2161
Nichols D, Arnold S, Weiss HL, et al. Pharmacogenomic potential in advanced cancer patients. Am J Health Syst Pharm. 2019;76(7):415-423. doi:10.1093/ajhp/zxy079
Reizine NM, Danahey K, Truong TM, et al. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022;128(8):1649-1657. doi:10.1002/cncr.34104
Shugg T, Ly RC, Rowe EJ, et al. Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. JCO Precis Oncol. 2022;6:e2100312. doi:10.1200/PO.21.00312
